1. Scrip
  2. >>Business

Ironwood Paying $1bn For VectivBio To Extend Its GI Franchise Beyond Linzess

Phase III Data For Apraglutide Due In Late 2023

 
• By Mandy Jackson

Ironwood said it believes VectivBio’s once-weekly GLP-2 analog apraglutide is differentiated from Takeda’s once-daily Gattex in short bowel syndrome and could generate $1bn in peak sales.

White jigsaw puzzle pieces connecting together on a light blue background
Ironwood sees VectivBio's apraglutide as a good fit in its gastrointestinal portfolio • Source: Shutterstock

Ironwood Pharmaceuticals, Inc. believes it has a clear winner on its hands with apraglutide for short bowel syndrome with intestinal failure (SBS-IF), and with its acquisition of VectivBio Holding AG, the company is betting $1bn that the next-generation GLP-2 analog will best Takeda Pharmaceutical Co. Ltd.’s first-generation Gattex (teduglutide).

Boston-based Ironwood announced on 22 May that it will pay $17 per share for VectivBio, an 80% premium to the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.